Patients with familial hypercholesterolemia (FH) are at high or very high risk for cardiovascular disease. Those with heterozygous FH (HeFH) often do not reach low-density lipoprotein cholesterol (LDL-C) targets with statin and ezetimibe therapy, and those with homozygous FH (HoFH) usually require additional lipid-modifying therapies. Drugs that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) offer a novel approach to reduce LDL-C. The monoclonal antibodies, alirocumab and evolocumab, given by subcutaneous injection every 2 or 4 weeks produce reductions in LDL-C of 50% to 60% in patients with HeFH, allowing many of them to achieve their LDL-C goals. Patients with HoFH show a reduced and more variable LDL-C response, which appears to depend on residual LDL receptor activity, and those with receptor-negative mutations may show no response. Inclisiran is a long-acting small interfering RNA therapeutic agent that inhibits the synthesis of PCSK9. Subcutaneous doses of 300 mg can reduce LDL-C by more than 50% for at least 6 months and the responses in HeFH and HoFH patients are similar to those achieved with monoclonal antibodies. These PCSK9 inhibitors are generally well tolerated and they provide a new opportunity for effective treatment for the majority of patients with FH.
Citations
Citations to this article as recorded by
Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors Ryosuke Tani, Keiji Matsunaga, Yuta Toda, Tomoko Inoue, Hai Ying Fu, Tetsuo Minamino Clinical Case Reports.2024;[Epub] CrossRef
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, Timo Z. Nazari-Shafti Cardiology and Therapy.2024; 13(1): 39. CrossRef
Technologies of gene editing and related clinical trials for the treatment of genetic and acquired diseases: a systematic review Wessam Sharaf-Eldin Egyptian Journal of Medical Human Genetics.2024;[Epub] CrossRef
Qualitative and Quantitative Effects of PCSK9 Inhibitors in familial Hypercholesterolemia: a Synthetic Review Aamina Shakir, Kyle Barron, Kalgi Modi Current Problems in Cardiology.2023; 48(4): 101550. CrossRef
Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression Peng Ye, Xiao-Min Jiang, Wei-Chun Qian, Juan Zhang Cardiovascular Drugs and Therapy.2023;[Epub] CrossRef
Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic Helen Huang, Keith S. K. Leung, Tulika Garg, Adele Mazzoleni, Goshen D. Miteu, Farida Zakariya, Wireko A. Awuah, Elaine T. S. Yin, Faaraea Haroon, Zarish Hussain, Narjiss Aji, Vikash Jaiswal, Gary Tse Clinical Cardiology.2023; 46(8): 831. CrossRef
Familial Hypercholesterolemia in Children. The Current State of the Problem Dinara I. Sadykova, Karina R. Salakhova, Liliya F. Galimova, Eugeniya S. Slastnikova, Chulpan D. Khaliullina Current Pediatrics.2023; 22(3): 231. CrossRef
Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium Marc Snel, Olivier S. Descamps Acta Cardiologica.2023; : 1. CrossRef
PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort Juan Vicente-Valor, Xandra García-González, Sara Ibáñez-García, María Esther Durán-García, Ana de Lorenzo-Pinto, Carmen Rodríguez-González, Irene Méndez-Fernández, Juan Carlos Percovich-Hualpa, Ana Herranz-Alonso, María Sanjurjo-Sáez Biomedicine & Pharmacotherapy.2022; 146: 112519. CrossRef
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia Shakir Ahamad, Shintu Mathew, Waqas A. Khan, Kishor Mohanan Drug Discovery Today.2022; 27(5): 1332. CrossRef
The biological relevance of PCSK9: when less is better… Majambu Mbikay, Michel Chrétien Biochemistry and Cell Biology.2022; 100(3): 189. CrossRef
Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park Metabolism.2022; 137: 155327. CrossRef
Homozygous Familial Hypercholesterolemia Lisa Young, Emily E. Brown, Seth S. Martin JACC: Case Reports.2022; 4(23): 101666. CrossRef
Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis Kristina Zubielienė, Gintarė Valterytė, Neda Jonaitienė, Diana Žaliaduonytė, Vytautas Zabiela Medicina.2022; 58(11): 1665. CrossRef
Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study Eric Bruckert, Sonia Caprio, Albert Wiegman, Min-Ji Charng, Cézar A. Zárate-Morales, Marie T. Baccara-Dinet, Garen Manvelian, Anne Ourliac, Michel Scemama, Stephen R. Daniels Arteriosclerosis, Thrombosis, and Vascular Biology.2022; 42(12): 1447. CrossRef